CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Minniti, C. P.
Right arrow Articles by Helman, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Minniti, C. P.
Right arrow Articles by Helman, L. J.

Cell Growth & Differentiation, Vol 6, Issue 3 263-269, Copyright © 1995 by American Association of Cancer Research


ARTICLES

Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype

CP Minniti, D Luan, C O'Grady, RG Rosenfeld, Y Oh and LJ Helman
Lombardi Cancer Center, Georgetown University Medical School, Washington, DC 20007, USA.

The objective of this study was to examine the role of insulin-like growth factor II (IGF-II) in the pathogenesis of human rhabdomyosarcomas (RMS). We have demonstrated previously that RMS express high levels of IGF-II mRNA, secrete IGF-II peptide, and express both IGF-I and IGF-II receptors. Moreover, we showed that IGF-II functions as an autocrine growth and motility factor in RMS. Since IGF-II is expressed at high levels in fetal muscle cells and RMS are tumors thought to derive from skeletal myoblasts arrested along the normal myogenic pathway, autocrine production of IGF-II by RMS may be an etiological event in the development of this tumor. We have developed a model system which enabled us to study the effects of endogenous IGF-II overprotection in muscle myoblasts. Human cDNA for pre-prohormone IGF-II was transfected into mouse myoblasts in order to achieve high, constant expression of this growth factor, which is normally down-regulated at the end of the differentiation process. Expression of high IGF-II levels resulted in: (a) an increased proliferative rate; (b) impairment of the ability to differentiate into myoblasts; and (c) acquisition of the capability of anchorage-independent growth. No changes in the expression of IGF-I receptors were noted. We conclude that IGF-II overexpression in muscle myoblasts induces morphological and biological changes typical of the malignant phenotype and represents a fundamental event in the pathogenesis of RMS and possibly of other embryonal tumors.


This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
J.-l. Liu, G.-r. Gao, X. Zhang, S.-f. Cao, C.-l. Guo, X. Wang, L.-j. Tong, J. Ding, W.-h. Duan, and L.-h. Meng
DW09849, a Selective Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Prevents PI3K Signaling and Preferentially Inhibits Proliferation of Cells Containing the Oncogenic Mutation p110{alpha} (H1047R)
J. Pharmacol. Exp. Ther., March 1, 2014; 348(3): 432 - 441.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. Li, J. Wang, X. Wang, N. Yang, S.-m. Chen, L.-j. Tong, C.-h. Yang, L.-h. Meng, and J. Ding
WJD008, a Dual Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin Inhibitor, Prevents PI3K Signaling and Inhibits the Proliferation of Transformed Cells with Oncogenic PI3K Mutant
J. Pharmacol. Exp. Ther., September 1, 2010; 334(3): 830 - 838.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Lu, D. Katsaros, A. Wiley, I. A. Rigault de la Longrais, H. A. Risch, M. Puopolo, and H. Yu
The Relationship of Insulin-Like Growth Factor-II, Insulin-Like Growth Factor Binding Protein-3, and Estrogen Receptor-{alpha} Expression to Disease Progression in Epithelial Ovarian Cancer
Clin. Cancer Res., February 15, 2006; 12(4): 1208 - 1214.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
W. J. Fredericks, K. Ayyanathan, M. Herlyn, J. R. Friedman, and F. J. Rauscher III
An Engineered PAX3-KRAB Transcriptional Repressor Inhibits the Malignant Phenotype of Alveolar Rhabdomyosarcoma Cells Harboring the Endogenous PAX3-FKHR Oncogene
Mol. Cell. Biol., July 15, 2000; 20(14): 5019 - 5031.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
L. Zhang, M. Kim, Y. H. Choi, B. Goemans, C. Yeung, Z. Hu, S. Zhan, P. Seth, and L. J. Helman
Diminished G1 Checkpoint after {gamma}-Irradiation and Altered Cell Cycle Regulation by Insulin-like Growth Factor II Overexpression
J. Biol. Chem., May 7, 1999; 274(19): 13118 - 13126.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
R. Zarrilli, M. Romano, S. Pignata, S. Casola, C. B. Bruni, and A. M. Acquaviva
Constitutive Insulin-like Growth Factor-II Expression Interferes with the Enterocyte-like Differentiation of CaCo-2 Cells
J. Biol. Chem., April 5, 1996; 271(14): 8108 - 8114.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1995 by the American Association of Cancer Research.